What happens when a patent expires on a branded drug?

A generic drug is a pharmaceutical that contains the same chemical substance as a drug that was originally branded and protected by patents, but once they expire, duplicates are often allowed for sale as so-called generics.

Some characteristics such as the manufacturing process, formulation, color, taste, and packaging may slightly differ, but given that the active pharmaceutical ingredient (API) is the same, the medical profile of generics is believed to be equivalent in performance to the original and therefore its route to market it much quicker.

In order to market them, manufacturers must still conduct studies to determine whether their version is bioequivalent to the original drug; specifically, that its active ingredient releases into the bloodstream at virtually the same speed and amount, but as the original was already proven safe, the testing is much quicker and requires a much smaller clinical study.

QUINTA-ANALYTICA’s bioanalytical department has vast experience in drug testing, and has developed and validated over 300 bioanalytical methods for APIs under GLP, GMP, and ICH/FDA and EMEA directives.

Get in touch with us today to discuss your testing needs.

Additional News

  • 3 September 2026

    Quinta-Analytica Expands HPLC Fleet to Strengthen Flexibility and Capacity for Clients

    New Thermo Scientific Vanquish Core joins an HPLC fleet of around 50 systems

  • 7 August 2026

    Quinta-Analytica at CPHI Milan 2026 – Meet Us at Conscio Group Stand 6N25

    Meet Quinta-Analytica at CPHI Milan 2026 as part of the Conscio Group team at Stand 6N25. Discuss your clinical, bioanalytical and analytical projects with our experts and arrange a meeting in advance.

  • 15 July 2026

    Quinta-Analytica Awarded the EcoVadis Gold Medal

    Quinta-Analytica has been awarded the EcoVadis Gold Medal after achieving an overall sustainability score of 84 out of 100. The result represents a substantial increase from 68 points in the previous assessment and places the company in the 97th percentile globally.